• Abdullah Durhan, Koray Koşmaz, Marlen Süleyman, Mesut Tez, Abdullah Şenlikci, Can Ersak, Yilmaz Ünal, Recep Pekcici, Fatih Karaahmet, Mehmet Şeneş, Ilknur Alkan Kuşabbi, Eylem Pinar Eser, and Sema Hücümenoğlu.
• Department of Surgical Oncology, Department of General Surgery, Ministry of Health Ankara Training and Research Hospital, Ankara, Turkey
• Turk J Med Sci. 2020 Aug 26; 50 (5): 1421-1427.

Background/AimTo investigate possible protective effects of Ankaferd Blood Stopper® (ABS) in an experimental liver ischemia reperfusion injury (IRI) model.Materials And MethodsThe study was carried out on 30 female rats separated into 3 groups as sham, control (IRI), and treatment (IRI + ABS) groups. In the IRI + ABS group, 0.5 mL/day ABS was given for 7 days before surgery. In the IRI and IRI + ABS groups, the hepatic pedicle was clamped for 30 min to apply ischemia. Then, after opening the clamp, 90-min reperfusion of the liver was provided. Blood and liver tissue samples were taken for biochemical and histopathological analyses.ResultsCompared to the sham group, the IRI group had significantly higher levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total oxidant status (TOS), malondialdehyde (MDA), fluorescent oxidant products (FOP) and lower expression of albumin and total antioxidant status (TAS) (P < 0.05). Compared to the IRI group, the IRI+ABS group showed lower expression of AST, ALT, TOS, MDA and FOP and higher expression of albumin and TAS (P < 0.05). In the histopathological analysis, congestion scores were statistically significantly lower in the IRI + ABS group than in the IRI group.ConclusionsABS has a strong hepatoprotective effect due to its antioxidant and antiinflammatory effects and could therefore be used as a potential therapeutic agent for IRI.This work is licensed under a Creative Commons Attribution 4.0 International License.

29 keywords...

hide…